Anti-alpha-V beta-3 recombinant humanized antibodies, nucleic acids encoding same and methods of use
The invention provides a Vitaxin antibody and a LM609 grafted antibody exhibiting selective binding affinity to alphavbeta3. The Vitaxin antibody consists of at least one Vitaxin heavy chain polypeptide and at least one Vitaxin light chain polypeptide or functional fragments thereof. Also provided a...
Saved in:
Main Authors | , |
---|---|
Format | Patent |
Language | English |
Published |
23.08.2001
|
Edition | 7 |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | The invention provides a Vitaxin antibody and a LM609 grafted antibody exhibiting selective binding affinity to alphavbeta3. The Vitaxin antibody consists of at least one Vitaxin heavy chain polypeptide and at least one Vitaxin light chain polypeptide or functional fragments thereof. Also provided are the Vitaxin heavy and light chain polypeptides and functional fragments. The LM609 grafted antibody consists of at least one CDR grafted heavy chain polypeptide and at least one CDR grafted light chain polypeptide or functional fragment thereof. Nucleic acids encoding Vitaxin and LM609 grafted heavy and light chains as well as nucleic acids encoding the parental non-human antibody LM609 are additionally provided. Functional fragments of such encoding nucleic acids are similarly provided. The invention also provides a method of inhibiting a function of alphavbeta3. The method consists of contacting alphavbeta3 with Vitaxin or a LM609 grafted antibody or functional fragments thereof under conditions which allow binding to alphavbeta3. Finally, the invention provides for a method of treating an alphavbeta3-mediated disease. The method consists of administering an effective amount of Vitaxin or a LM609 grafted antibody or functional fragment thereof under conditions which allow binding to alphavbeta3. |
---|---|
AbstractList | The invention provides a Vitaxin antibody and a LM609 grafted antibody exhibiting selective binding affinity to alphavbeta3. The Vitaxin antibody consists of at least one Vitaxin heavy chain polypeptide and at least one Vitaxin light chain polypeptide or functional fragments thereof. Also provided are the Vitaxin heavy and light chain polypeptides and functional fragments. The LM609 grafted antibody consists of at least one CDR grafted heavy chain polypeptide and at least one CDR grafted light chain polypeptide or functional fragment thereof. Nucleic acids encoding Vitaxin and LM609 grafted heavy and light chains as well as nucleic acids encoding the parental non-human antibody LM609 are additionally provided. Functional fragments of such encoding nucleic acids are similarly provided. The invention also provides a method of inhibiting a function of alphavbeta3. The method consists of contacting alphavbeta3 with Vitaxin or a LM609 grafted antibody or functional fragments thereof under conditions which allow binding to alphavbeta3. Finally, the invention provides for a method of treating an alphavbeta3-mediated disease. The method consists of administering an effective amount of Vitaxin or a LM609 grafted antibody or functional fragment thereof under conditions which allow binding to alphavbeta3. |
Author | SCOTT M. GLASER WILLIAM D. HUSE |
Author_xml | – fullname: SCOTT M. GLASER – fullname: WILLIAM D. HUSE |
BookMark | eNqNijsOwjAQBV1Awe8OewDcEEFEmSAQBwDaaGO_JJbidYSdhtPjggNQjd68WauFBMFK2UqS0zxOA-sXtUisC3rDBN86YUk0zJ7FfWApL9cG6xD3JLMZ4QyxcTYSxGQvPUX2yJ0ljzSE_ISO5oitWnY8Rux-3Ci6XR-Xu8YUGsSJDQSpqZ5lUR5P57o-FH8kXySZP2U |
ContentType | Patent |
DBID | EVB |
DatabaseName | esp@cenet |
DatabaseTitleList | |
Database_xml | – sequence: 1 dbid: EVB name: esp@cenet url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP sourceTypes: Open Access Repository |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Chemistry Sciences |
Edition | 7 |
ExternalDocumentID | AU737569BB2 |
GroupedDBID | EVB |
ID | FETCH-epo_espacenet_AU737569BB23 |
IEDL.DBID | EVB |
IngestDate | Fri Jul 19 15:59:55 EDT 2024 |
IsOpenAccess | true |
IsPeerReviewed | false |
IsScholarly | false |
Language | English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-epo_espacenet_AU737569BB23 |
Notes | Application Number: AU19980061391 |
OpenAccessLink | https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20010823&DB=EPODOC&CC=AU&NR=737569B2 |
ParticipantIDs | epo_espacenet_AU737569BB2 |
PublicationCentury | 2000 |
PublicationDate | 20010823 |
PublicationDateYYYYMMDD | 2001-08-23 |
PublicationDate_xml | – month: 08 year: 2001 text: 20010823 day: 23 |
PublicationDecade | 2000 |
PublicationYear | 2001 |
RelatedCompanies | IXSYS, INCORPORATED |
RelatedCompanies_xml | – name: IXSYS, INCORPORATED |
Score | 2.5423217 |
Snippet | The invention provides a Vitaxin antibody and a LM609 grafted antibody exhibiting selective binding affinity to alphavbeta3. The Vitaxin antibody consists of... |
SourceID | epo |
SourceType | Open Access Repository |
SubjectTerms | BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS VINEGAR WINE |
Title | Anti-alpha-V beta-3 recombinant humanized antibodies, nucleic acids encoding same and methods of use |
URI | https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20010823&DB=EPODOC&locale=&CC=AU&NR=737569B2 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LS8NAEB5KFfWmVbG-2IPk5GLbTbLNoUiTtBShD6QtvZXsZoM5NCkmRfDXO7tt1Yve9sWwD2ZmZ3fmG4CHtssjJ2KMJnji1G5Kh0aeoyhvCbet4dcbUhuKw5E7mNkvC2dRgbd9LIzBCf0w4IjIURL5vTTyev3ziBUa38riSaTYlD_3p53Q2lvHTf1xZIV-pzcZh-PACgK0JK3Ra4cz7riej8L6QF-iNcp-b-7rmJT1b4XSP4XDCdLKyjOoqKwGx8E-71oNjoa7724s7jivOIe4m5UpNZGxdE4ETo4yoq3ZlTC-LMQk20s_VUywlopcewc-kkzDFaeSRDKNC6JBK7WuIkW0UjguJtsE0gXJE7Ip1AWQfm8aDChOd_m9M8vubLcuv8UuoZrlmboCwptKcq-dNKQUduJFUUtxrhGMPCWcuMHqUP-TzPU_fTdwsvXAQt5it1At3zfqDlVyKe7Nbn4BnsiRdQ |
link.rule.ids | 230,309,786,891,25594,76903 |
linkProvider | European Patent Office |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LT8JAEJ4QNOJNUSM-92B6ciNQ2qUHYmgLQeUVA4Qb6W63sQdaYktM_PXOLqBe9LavbPaR2cm3M_MNwF3TZoEVmCaN8MZpoyYsGjiWpKzO7aaiX68KBRQHQ7s3bTzPrXkB3naxMJon9EOTI6JECZT3XL_Xq59PLF_7VmYPPMam9LE7afnGDh3XlOHI8N1WZzzyR57heYgkjeFri5nMsh0XH-s9hoBQA6WZq2JSVr8VSvcI9sc4V5IfQ0EmZSh5u7xrZTgYbM3dWNxKXnYCYTvJY6ojY-mMcFwcNYlCs0uufVmITrYXf8qQYC3mqfIOvCeJoiuOBQlEHGZEkVYqXUWyYClxXEg2CaQzkkZknclTIN3OxOtRXO7i-2QW7el2X27dPINikibyHAirScGcZlQVgjciJwjqkjHFYORIboVVswKVP6e5-KfvFkq9yaC_6D8NXy7hcOONhXJmXkExf1_La1TPOb_RJ_sFkYmUXw |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=Anti-alpha-V+beta-3+recombinant+humanized+antibodies%2C+nucleic+acids+encoding+same+and+methods+of+use&rft.inventor=SCOTT+M.+GLASER&rft.inventor=WILLIAM+D.+HUSE&rft.date=2001-08-23&rft.externalDBID=B2&rft.externalDocID=AU737569BB2 |